InnoCan Pharma (TSE:INNO) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Innocan Pharma has reported impressive financial results for the third quarter of 2024, with a 174% year-over-year increase in 9-month revenues to $24 million, primarily driven by its subsidiary BI Sky Global Ltd. The company has also turned its financial performance around, achieving a net profit of $0.3 million compared to a net loss in the previous year, showcasing strong operational momentum and successful product introductions.
For further insights into TSE:INNO stock, check out TipRanks’ Stock Analysis page.